Longeveron Inc - Ordinary Shares - Class A

NASDAQ:LGVN  
6.60
-0.72 (-9.84%)
Products

FDA Grants Orphan Drug Designation For Longeveron's Lomecel-B To Treat Infants With Hypoplastic Left Heart Syndrome

Published: 12/06/2021 15:39 GMT
Longeveron Inc - Ordinary Shares - Class A (LGVN) - Longeveron Granted Orphan Drug Designation by FDA for Lomecel-b to Treat Infants With Hypoplastic Left Heart Syndrome (hlhs).